Scholarlink

Purpose <p>Glucagon-like peptide-1 receptor agonists exhibit neuroprotective and anti-inflammatory effects; however, their role as perineural adjuvants in peripheral nerve blocks has not been investigated. We evaluated whether perineural liraglutide prolongs bupivacaine-induced sciatic nerve block and attenuates local tissue inflammation in a rat model.</p> Methods <p>Forty male Wistar rats were randomized into five groups. Group I received perineural bupivacaine alone (0.3&#xa0;ml 0.5% bupivacaine + 0.2&#xa0;ml saline). Groups II and III received perineural bupivacaine (0.3&#xa0;ml 0.5%) combined with liraglutide (0.2&#xa0;ml; 1.8 or 3.6&#xa0;mg/kg, respectively). Group IV received perineural liraglutide alone (0.5&#xa0;ml, 3.6&#xa0;mg/kg). Group V received perineural bupivacaine (0.3&#xa0;ml 0.5% + 0.2&#xa0;ml saline) and concurrently systemic liraglutide (3.6&#xa0;mg/kg, intraperitoneal). Sciatic nerve block was performed under nerve stimulation. Sensory, motor, and proprioceptive functions were assessed every 10&#xa0;min until complete recovery. At 24&#xa0;h, sciatic nerves were harvested for blinded histopathological evaluation.</p> Results <p>High-dose perineural liraglutide prolonged bupivacaine-induced block duration compared with bupivacaine alone (sensory: 170 [160–180] vs 120 [107.5–130] min, <i>p</i> = 0.009; motor: 160 [160–170] vs 115 [100–120] min, p = 0.007; proprioceptive: 170 [167.5–170] vs 115 [100–122.5] min, <i>p</i> = 0.009). Systemic liraglutide did not reproduce this effect. Histopathologically, perineural inflammation was reduced in liraglutide-treated groups (<i>p</i> &lt; 0.001), with no evidence of myelin damage at 24&#xa0;h.</p> Conclusion <p>Perineural liraglutide produces dose-dependent prolongation of bupivacaine sciatic nerve block and reduces perineural inflammation without myelin toxicity. These findings provide proof-of-concept for liraglutide as a novel perineural adjuvant, warranting extended neurotoxicity and further translational studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model

  • 期刊论文

  • 发表日期：

    2026年6月30日

查看全文
  • Mustafa Büyükcavlak,
  • Mehmet Sarı,
  • Cansu Çiftci,
  • Seda Tas Ayçiçek,
  • Pembe Oltulu,
  • Sadettin Çiftci

摘要

Purpose

Glucagon-like peptide-1 receptor agonists exhibit neuroprotective and anti-inflammatory effects; however, their role as perineural adjuvants in peripheral nerve blocks has not been investigated. We evaluated whether perineural liraglutide prolongs bupivacaine-induced sciatic nerve block and attenuates local tissue inflammation in a rat model.

Methods

Forty male Wistar rats were randomized into five groups. Group I received perineural bupivacaine alone (0.3 ml 0.5% bupivacaine + 0.2 ml saline). Groups II and III received perineural bupivacaine (0.3 ml 0.5%) combined with liraglutide (0.2 ml; 1.8 or 3.6 mg/kg, respectively). Group IV received perineural liraglutide alone (0.5 ml, 3.6 mg/kg). Group V received perineural bupivacaine (0.3 ml 0.5% + 0.2 ml saline) and concurrently systemic liraglutide (3.6 mg/kg, intraperitoneal). Sciatic nerve block was performed under nerve stimulation. Sensory, motor, and proprioceptive functions were assessed every 10 min until complete recovery. At 24 h, sciatic nerves were harvested for blinded histopathological evaluation.

Results

High-dose perineural liraglutide prolonged bupivacaine-induced block duration compared with bupivacaine alone (sensory: 170 [160–180] vs 120 [107.5–130] min, p = 0.009; motor: 160 [160–170] vs 115 [100–120] min, p = 0.007; proprioceptive: 170 [167.5–170] vs 115 [100–122.5] min, p = 0.009). Systemic liraglutide did not reproduce this effect. Histopathologically, perineural inflammation was reduced in liraglutide-treated groups (p < 0.001), with no evidence of myelin damage at 24 h.

Conclusion

Perineural liraglutide produces dose-dependent prolongation of bupivacaine sciatic nerve block and reduces perineural inflammation without myelin toxicity. These findings provide proof-of-concept for liraglutide as a novel perineural adjuvant, warranting extended neurotoxicity and further translational studies.